NCT05450562: Dose Escalation and Expansion Study of SAR444200 in Adult Participants With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: GPC3
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumor tissue that is positive GPC3 expression
Exclusions: Patients with known active brain or leptomeningeal metastases

Comments are closed.

Up ↑